TORONTO, May 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced receipt of an...
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced receipt of a...
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its...
TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo...
TORONTO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the œCompany or œPharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority...
TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the œCompany or œPharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, is pleased to provide an update...
FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher™s commitment toward unlocking the potential of ketamine for unmet medical needs TORONTO, Sept. 27, 2023 (GLOBE...
TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the œCompany or œPharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to...
TORONTO, July 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to...
Company funded to meet upcoming milestones over the next 24 months Expected FDA approval for KETARX„¢ (racemic ketamine) via the ANDA pathway in Q1-2024 and international approvals after that Company...